Literature DB >> 16380162

Generation of a long-lasting, protective, and neutralizing antibody response to the ranavirus FV3 by the frog Xenopus.

Gregory D Maniero1, Heidi Morales, Jennifer Gantress, Jacques Robert.   

Abstract

Xenopus serves as an experimental model to evaluate the contribution of adaptive immunity in host susceptibility to emerging ranaviral diseases that may contribute to amphibian population declines. It has been previously shown that following a secondary infection with the ranavirus frog virus 3 (FV3), adult Xenopus more rapidly clear FV3 and generate specific anti-FV3 IgY antibodies. We have further evaluated the potency and persistence of the Xenopus antibody response against FV3. Frogs inoculated with FV3 (without adjuvant) up to 15 months after priming produce specific, thymus-dependent anti-FV3 IgY antibodies detectable from 10 days to 8 weeks post-infection. These antisera from boosted frogs are neutralizing in vitro and provide partial passive protection to susceptible larvae when they are injected a few minutes before FV3 inoculation. These results with Xenopus suggest that other anuran amphibians are likely to develop effective long-lasting protective humoral immunity after an initial viral exposure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16380162     DOI: 10.1016/j.dci.2005.09.007

Source DB:  PubMed          Journal:  Dev Comp Immunol        ISSN: 0145-305X            Impact factor:   3.636


  23 in total

1.  Developmental exposure to chemicals associated with unconventional oil and gas extraction alters immune homeostasis and viral immunity of the amphibian Xenopus.

Authors:  Jacques Robert; Connor C McGuire; Susan Nagel; B Paige Lawrence; Francisco De Jesús Andino
Journal:  Sci Total Environ       Date:  2019-03-26       Impact factor: 7.963

2.  Susceptibility of Xenopus laevis tadpoles to infection by the ranavirus Frog-Virus 3 correlates with a reduced and delayed innate immune response in comparison with adult frogs.

Authors:  Francisco De Jesús Andino; Guangchun Chen; Zhenghui Li; Leon Grayfer; Jacques Robert
Journal:  Virology       Date:  2012-07-21       Impact factor: 3.616

3.  Xenopus-FV3 host-pathogen interactions and immune evasion.

Authors:  Robert Jacques; Eva-Stina Edholm; Sanchez Jazz; Torres-Luquis Odalys; De Jesús Andino Francisco
Journal:  Virology       Date:  2017-06-16       Impact factor: 3.616

Review 4.  Evolution of B cell immunity.

Authors:  David Parra; Fumio Takizawa; J Oriol Sunyer
Journal:  Annu Rev Anim Biosci       Date:  2013-01       Impact factor: 8.923

5.  Characterization of primary and memory CD8 T-cell responses against ranavirus (FV3) in Xenopus laevis.

Authors:  Heidi D Morales; Jacques Robert
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

6.  Innate immune responses and permissiveness to ranavirus infection of peritoneal leukocytes in the frog Xenopus laevis.

Authors:  Heidi D Morales; Lara Abramowitz; Jacqueline Gertz; Jessica Sowa; Ashley Vogel; Jacques Robert
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

7.  Antibody dependent enhancement of frog virus 3 infection.

Authors:  Heather E Eaton; Emily Penny; Craig R Brunetti
Journal:  Virol J       Date:  2010-02-18       Impact factor: 4.099

Review 8.  A prominent role for invariant T cells in the amphibian Xenopus laevis tadpoles.

Authors:  Jacques Robert; Eva-Stina Edholm
Journal:  Immunogenetics       Date:  2014-06-05       Impact factor: 2.846

9.  Differential transcription of fathead minnow immune-related genes following infection with frog virus 3, an emerging pathogen of ectothermic vertebrates.

Authors:  Kwang Cheng; B Lynn Escalon; Jacques Robert; V Gregory Chinchar; Natàlia Garcia-Reyero
Journal:  Virology       Date:  2014-04-01       Impact factor: 3.616

10.  Evidence for directional selection at a novel major histocompatibility class I marker in wild common frogs (Rana temporaria) exposed to a viral pathogen (Ranavirus).

Authors:  Amber G F Teacher; Trenton W J Garner; Richard A Nichols
Journal:  PLoS One       Date:  2009-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.